Replies to post #140906 on Biotech Values

[DewDiligence]

From the same PKI newswire:

PerkinElmer tweaked its full-year forecast range and now expects to earn $2.00 to $2.05 per share excluding items. (It had previously forecast $1.98 to $2.04 per share.)

…The Human Health division, which includes neonatal testing and other diagnostic equipment, saw sales jump 26 percent to $254.0 million [this includes the effect of the CALP acquisition].

PKI also reported >20% organic growth (i.e. excluding the CALP acquisition) in the BRIC countries (http://seekingalpha.com/article/534591-perkinelmer-s-ceo-discusses-q1-2012-results-earnings-call-transcript ).

[DewDiligence]

PKI addendum to #msg-74915032: With no more worries about WAT and TMO, PKI closed the day +3%, within a hair of its 12-month high. The stock is +60% during the past five months.